Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Does obesity influence target organ damage and outcomes in patients with malignant phase hypertension? The West Birmingham Malignant Hypertension Project.

Shantsila A, Lane DA, Beevers DG, Lip GY.

Hypertens Res. 2013 Jun;36(6):546-9. doi: 10.1038/hr.2012.222. Epub 2013 Feb 14.

PMID:
23407241
2.

Lack of impact of pulse pressure on outcomes in patients with malignant phase hypertension: the West Birmingham Malignant Hypertension study.

Shantsila A, Lane DA, Beevers DG, Lip GY.

J Hypertens. 2012 May;30(5):974-9. doi: 10.1097/HJH.0b013e3283526e47.

PMID:
22495136
3.

Overweight, obesity, and the development of stage 3 CKD: the Framingham Heart Study.

Foster MC, Hwang SJ, Larson MG, Lichtman JH, Parikh NI, Vasan RS, Levy D, Fox CS.

Am J Kidney Dis. 2008 Jul;52(1):39-48. doi: 10.1053/j.ajkd.2008.03.003. Epub 2008 Apr 28.

4.

Is there any survival advantage of obesity in Southern European haemodialysis patients?

Chazot C, Gassia JP, Di Benedetto A, Cesare S, Ponce P, Marcelli D.

Nephrol Dial Transplant. 2009 Sep;24(9):2871-6. doi: 10.1093/ndt/gfp168. Epub 2009 Apr 15.

6.

Microalbuminuria and left ventricular mass in overweight and obese hypertensive patients: role of the metabolic syndrome.

Guerra F, Mancinelli L, Buglioni A, Pierini V, Rappelli A, Dessì-Fulgheri P, Sarzani R.

High Blood Press Cardiovasc Prev. 2011 Dec 1;18(4):195-201. doi: 10.2165/11593650-000000000-00000.

PMID:
22283674
7.

Overweight/obesity revisited as a predictive risk factor in primary IgA nephropathy.

Berthoux F, Mariat C, Maillard N.

Nephrol Dial Transplant. 2013 Nov;28 Suppl 4:iv160-6. doi: 10.1093/ndt/gft286. Epub 2013 Sep 11.

8.

Influence of obesity on progression of non-diabetic chronic kidney disease: a retrospective cohort study.

Othman M, Kawar B, El Nahas AM.

Nephron Clin Pract. 2009;113(1):c16-23. doi: 10.1159/000228071. Epub 2009 Jul 10.

PMID:
19590231
9.

Obesity is a strong determinant of hypertensive target organ damage in young-to-middle-age patients.

Palatini P, Saladini F, Mos L, Benetti E, Bortolazzi A, Cozzio S, Casiglia E.

Int J Obes (Lond). 2013 Feb;37(2):224-9. doi: 10.1038/ijo.2012.32. Epub 2012 Mar 6.

PMID:
22391882
10.

Association of body mass index with decline in residual kidney function after initiation of dialysis.

Drechsler C, de Mutsert R, Grootendorst DC, Boeschoten EW, Krediet RT, le Cessie S, Wanner C, Dekker FW; NECOSAD Study Group.

Am J Kidney Dis. 2009 Jun;53(6):1014-23. doi: 10.1053/j.ajkd.2008.11.027. Epub 2009 Feb 13.

PMID:
19217702
11.

Impact of overweight and obesity on cardiac benefit of antihypertensive treatment.

Gerdts E, de Simone G, Lund BP, Okin PM, Wachtell K, Boman K, Nieminen MS, Dahlöf B, Devereux RB.

Nutr Metab Cardiovasc Dis. 2013 Feb;23(2):122-9. doi: 10.1016/j.numecd.2011.03.008. Epub 2011 Jul 19.

PMID:
21775111
12.

Underweight rather than overweight is associated with higher prevalence of hypertension: BP vs BMI in haemodialysis population.

Salahudeen AK, Fleischmann EH, Bower JD, Hall JE.

Nephrol Dial Transplant. 2004 Feb;19(2):427-32.

13.

The impact of obesity on the short-term and long-term outcomes after percutaneous coronary intervention: the obesity paradox?

Gruberg L, Weissman NJ, Waksman R, Fuchs S, Deible R, Pinnow EE, Ahmed LM, Kent KM, Pichard AD, Suddath WO, Satler LF, Lindsay J Jr.

J Am Coll Cardiol. 2002 Feb 20;39(4):578-84.

14.

[Obesity as a risk factor of chronic kidney disease in patients undergoing primary angioplasty].

Bachórzewska-Gajewska H, Małyszko J, Małyszko J, Poniatowski B, Musiał W, Dobrzycki S, Kinalska I.

Pol Arch Med Wewn. 2006 Oct;116(4):916-23. Polish.

PMID:
18416292
15.

Obesity paradox in patients with hypertension and coronary artery disease.

Uretsky S, Messerli FH, Bangalore S, Champion A, Cooper-Dehoff RM, Zhou Q, Pepine CJ.

Am J Med. 2007 Oct;120(10):863-70.

PMID:
17904457
16.

Complications and survival of 315 patients with malignant-phase hypertension.

Lip GY, Beevers M, Beevers DG.

J Hypertens. 1995 Aug;13(8):915-24.

PMID:
8557970
17.

Body mass index and cardiovascular risk factors and biomarkers in hemodialysis patients.

Bossola M, Giungi S, Panocchia N, Vulpio C, Luciani G, Tazza L.

J Nephrol. 2008 Mar-Apr;21(2):197-204.

PMID:
18446714
18.

Marked association between obesity and glomerular hyperfiltration: a cross-sectional study in an African population.

Wuerzner G, Pruijm M, Maillard M, Bovet P, Renaud C, Burnier M, Bochud M.

Am J Kidney Dis. 2010 Aug;56(2):303-12. doi: 10.1053/j.ajkd.2010.03.017. Epub 2010 Jun 9.

PMID:
20538392
19.

Does renal function improve after diagnosis of malignant phase hypertension?

Lip GY, Beevers M, Beevers DG.

J Hypertens. 1997 Nov;15(11):1309-15.

PMID:
9383181
20.
Items per page

Supplemental Content

Write to the Help Desk